日本MHLW批准Invivoscribe公司的LeukoStrat CDx FLT3突变试剂盒作为第一三共制药公司的Quizartinib的伴随诊断，用于复发/难治性FLT3-ITD AML的治疗。 扩展使用包括收集在EDTA的样本marketing2022-01-03T02:51:50+00:00June 19th, 2019|2019 Press Releases, Press Releases| 更多详细信息
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignanciesmarketing2021-02-26T19:10:45+00:00May 21st, 2019|2019 Press Releases, Press Releases| 更多详细信息
Invivoscribe将在2019年旧金山生物技术展示™上发表演讲wmm2022-01-03T02:52:03+00:00January 3rd, 2019|2019 Press Releases, Press Releases| 更多详细信息
US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the USInvivoscribe also Receives National Reimbursement for CDx Assay in Japanmarketing2021-02-26T19:11:02+00:00November 29th, 2018|2018 Press Releases, Press Releases| 更多详细信息
Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinibmarketing2021-02-26T19:11:39+00:00November 19th, 2018|2018 Press Releases, Press Releases| 更多详细信息
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japanmarketing2021-02-26T19:11:48+00:00November 19th, 2018|2018 Press Releases, Press Releases| 更多详细信息
Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)marketing2021-02-26T19:12:02+00:00September 27th, 2018|2018 Press Releases, Press Releases| 更多详细信息
Invivoscribe Announces a Regional “Center of Excellence” Reference Laboratory in Beirut to Offer Specialized Gene Panelsmarketing2021-02-26T19:12:15+00:00May 9th, 2018|2018 Press Releases, Press Releases| 更多详细信息
Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutationsmarketing2021-02-26T19:12:23+00:00May 8th, 2018|2018 Press Releases, Press Releases| 更多详细信息
Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Softwarewmm2021-02-26T19:12:40+00:00November 7th, 2017|2017 Press Releases, Press Releases| 更多详细信息
